Key Takeaways
- Serious eye complications are uncommon. The optic nerve concern has been linked mainly to semaglutide, the active ingredient in Ozempic and Wegovy, not to all GLP-1 drugs in this family.
- Sudden, painless vision loss in one eye needs to be seen the same day. Vision loss with a severe headache or neurologic symptoms is a 911 emergency.
- Diabetes, existing retinal disease, or a crowded optic nerve raise your risk.
- An eye exam early in treatment documents your optic nerve and retina, so any future change is measured against your own eyes rather than an average.
Millions of people are taking GLP-1 medications like Ozempic or Wegovy, and the headlines about vision loss have made a lot of them nervous. Patients bring this up in my exam room nearly every week, and they deserve a straight answer rather than a scare or a shrug.
Yes, these medications have been associated with rare but serious eye conditions, but serious complications are uncommon, and early research to this point is observational.
Medications like Ozempic, Wegovy, and Rybelsus contain semaglutide, while other GLP-1’s like Mounjaro and Zepbound contain tirzepatide, a related but different molecule. At this point, nearly all of the research related to vision relates to semaglutide.
When Is a Vision Change an Emergency?
Some vision changes need same-day attention, and not all of them need the same kind. This is the part I would want a family member to know.
Call for a same-day eye evaluation:
- Sudden painless vision loss in one eye
- Loss of the top or bottom half of your vision in one eye
- Colors looking washed out or dull in one eye
- A new shadow, curtain, or dark spot
- Sudden flashes of light or a new shower of floaters (not specific to these medications, but always urgent)
For anything on that list, contact our office or seek urgent eye care the same day.
Call 911 or go to the emergency room if you have a vision change along with:
- Severe headache or scalp tenderness
- Jaw pain while chewing
- Weakness or numbness
- Facial drooping
- Trouble speaking
I separate these two lists because sudden vision loss can have different causes and levels of urgency. One condition that may be associated with these medications is nonarteritic anterior ischemic optic neuropathy (NAION). There is also an arteritic form, which is caused by giant cell arteritis and requires immediate treatment to help prevent permanent vision loss. If you’re over 50 and experience sudden vision loss along with a severe headache, scalp tenderness, or jaw pain while chewing, seek emergency medical care right away.
Please do not stop your medication on your own. That decision belongs with the patient and the prescribing physician.
Which Eye Problems Have Been Linked to These Medications?
Worsening of Diabetic Retinopathy
If you already have diabetic changes in your retina, this section applies to you.
In clinical trials, diabetic retinopathy was reported in 4.0% of treated patients versus 2.7% of placebo-treated patients. In the two-year SUSTAIN-6 trial, the adjudicated complications endpoint occurred in 3.0% versus 1.8%.
The number I find most useful in the exam room is this one: in that same trial, the increased risk fell almost entirely on patients who already had retinopathy before starting:
- Patients with existing retinopathy: 8.2% compared with 5.2%
- Patients with no known retinopathy: 0.7% compared with 0.4%
We have known for decades that lowering blood sugar quickly can temporarily worsen retinopathy, long before these medications existed. That remains the likeliest explanation.
What does this mean for you?
This is not an argument against the medication. It is an argument for documenting the retina before treatment begins and following it closely through the first 12 to 18 months.
NAION: Sudden Optic Nerve Vision Loss
NAION is sometimes described as a stroke of the optic nerve. Blood flow to the nerve head drops suddenly, causing painless vision loss in one eye. Often the top or bottom half of the visual field can worsen over several days. About a third of patients regain a little vision. For most, the loss is permanent.
How Common Is NAION?
It helps to start with how uncommon this is. NAION affects between 2 and 10 people per 100,000 each year.
Most who develop it have what we call a “disc at risk,” which is a small, crowded nerve head with little or no central cup.
Other risk factors include:
- Diabetes
- High blood pressure
- Cardiovascular disease
- Sleep apnea
These are risk factors on their own, apart from any medication.
What Do We Know About Semaglutide and NAION?
In May 2026, the American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society published a joint consensus statement.
Their conclusion was that a possible association with semaglutide exists, but causation has not been shown.
If the risk is real, it is likely about a twofold increase over that already low baseline.
That is well below the 2024 Harvard study behind most headlines, which reported fourfold to sevenfold figures. That study ran at a single referral center treating most of its region’s NAION cases and never compared blood sugar control between groups, which were limitations the panel concluded likely inflated its numbers.
What Does the Risk Look Like in Real Numbers?
For absolute risk, the most useful data arrived in July 2026, when two large cohort studies were published in Annals of Internal Medicine.
Among patients with type 2 diabetes, those on one of these medications had roughly:
- 8.5 cases of ischemic optic neuropathy per 10,000 over 18 months
- Compared with about 5.5 cases per 10,000 on a different diabetes drug
- That’s roughly 3 additional cases per 10,000
Those figures come from diabetic populations, so I would not apply them to someone taking a GLP-1 for weight loss alone.
A note on the numbers:
As Andrew Morgenstern, OD, of the American Optometric Association put it, “a low risk of a big number is a big risk.” Rare events can add up across tens of millions of patients.
The Research Is Still Evolving
The findings are not unanimous. Several large analyses have found no increased risk at all, while one found a lower risk among diabetic patients taking semaglutide. Animal research even suggests that this class may protect retinal nerve tissue, which is part of why researchers doubt direct toxicity.
Wet Macular Degeneration
One large Canadian study of diabetic adults over 65 found patients on these medications were about twice as likely to be diagnosed with wet macular degeneration.
The numbers were very small:
- Approximately 93 cases among 46,334 exposed patients
- 88 cases among 92,668 unexposed patients
Other groups have not reproduced it, and the study could not account for smoking. I would call this something worth watching, but not necessarily an established risk. For now, this is something worth watching rather than an established risk.
What Do Regulators and Eye Doctors Recommend?
In June 2025, the European Medicines Agency added NAION to the product information for Ozempic, Wegovy, and Rybelsus as a very rare side effect and recommended stopping semaglutide if it is confirmed. The United Kingdom followed in February 2026. As of this writing, the FDA has not added it to the American label; the difference in labeling status is not a disagreement about the data.
The American societies declined to endorse stopping automatically. Their reasons are solid: discontinuing carries real risks for patients managing obesity, difficult diabetes, or heart disease. They concluded the decision belongs to the patient, the eye doctor, and the prescriber together. Thoughtful people are reading the same evidence and landing in different places, which is why each patient’s individual measurements are critical.
Who Should Have Their Eyes Checked First?
What Happens at This Exam?
In our practice, we built a specific protocol for patients on these medications. A basic vision screening (the kind that checks whether you can read the chart) measures none of what matters here. A complete baseline GLP-1 evaluation includes:
- A comprehensive dilated eye exam
- Optical coherence tomography (OCT) to document your retinal nerve fiber layer thickness and optic nerve measurements
- A full optic nerve evaluation which entails a clinical exam, OCT, and fundus imaging to document your cup-to-disc ratio
- Electroretinography (ERG), which measures retinal cell function and risk for further diabetic eye disease
- Ocular wellness imaging for a high-resolution record of your retina and optic nerve
- A review of your medication, diabetes history, and A1c trends
- Direct communication with your prescribing physician when warranted
A crowded optic nerve is one of the most important anatomic risk factors for NAION, and this exam can identify it. And if a problem ever develops, your measurements from before treatment let us tell a real change from the way your eyes have always looked. Patients with diabetes should also keep up their regular diabetic eye exams.
Frequently Asked Questions
Can Ozempic cause blurry vision, and does it go away?
Temporary blurring in the first few weeks is fairly common and usually reflects rapid changes in blood sugar. It typically settles as your body adjusts, and early worsening of diabetic retinopathy is often temporary too. NAION is the exception since vision loss is usually permanent, and nothing we have reliably reverses it. That difference is the whole argument for documenting your eyes early.
Should I have my eyes examined before I start treatment?
Yes, particularly with diabetes, existing retinal disease, a crowded optic nerve, a prior episode of NAION, high blood pressure, sleep apnea, or if you are over 65. An exam before you begin treatment gives us a precise point of comparison for every visit afterward. You can book an appointment online.
How common is NAION with semaglutide?
It is rare. NAION affects roughly 2 to 10 people per 100,000 per year overall. European regulators classify it as a very rare side effect, up to about 1 in 10,000 patients. In one 2026 study of type 2 diabetes patients, those on this class of medication saw about 8.5 cases per 10,000 over 18 months versus 5.5 per 10,000 on a different diabetes drug. Well over 9,990 of every 10,000 patients will not experience this.
Is Mounjaro linked to the same eye risks as Ozempic?
Not based on what we know today. Mounjaro and Zepbound contain tirzepatide, a dual GIP/GLP-1 receptor agonist; Ozempic and Wegovy contain semaglutide. Safety monitoring has not detected the same optic nerve signal with tirzepatide.
I would not treat that as settled, though. Isolated cases have been reported; the major 2026 studies analyzed these drugs as a single class, and the consensus panel specifically cautioned against assuming the risk belongs to semaglutide alone. Tirzepatide is more potent and needs further study. Absence of a clear difference is not proof of safety.
What should I do if my vision changes while I am on this medication?
Have your eyes examined right away, but do not stop the medication on your own. Guidance genuinely differs here. The decision should be made jointly by you, your eye doctor, and your prescriber, because stopping carries its own risks. That applies to semaglutide specifically, not to every drug in this family. And if your vision change comes with a severe headache, jaw pain, weakness, or trouble speaking, that is a 911 call.
Where can I have this exam done in Spartanburg?
We are located at 142 Fernwood Drive on Spartanburg’s east side. We care for families from Greenville, Greer, Boiling Springs, Roebuck, Inman, and across the Upstate and Western North Carolina. You can request an exam online or call our office at 864-308-8812.
Protect Your Vision While You Protect Your Health
These medications are really helping a lot of people, and nothing here argues against taking one. What I tell patients is that four things can be said plainly:
- This optic nerve condition is rare.
- The absolute numbers are small.
- An exam early in treatment costs you one visit.
- And sudden vision loss is always urgent, no matter what the cause might be.
Much of the rest is still being worked out, and I would rather tell you that than pretend otherwise. But after more than 20 years in practice, the pattern I keep seeing is the same: the patients who do best are the ones we met before something changed. Your primary care physician is guiding your GLP-1 treatment, and your eye doctor can help manage your sight so you continue to see well. Those two jobs work best when the people doing them talk to each other, and we are glad to make that call.
If you have started one of these medications, or you are about to, book an appointment with our team at Bella Vision. We would rather have your measurements on file and never need them than wish we had them.
References
Evidence current as of July 2026.
1. American Academy of Ophthalmology and North American Neuro-Ophthalmology Society. Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement by NANOS and the American Academy of Ophthalmology. Approved by the AAO Board of Trustees, March 2026; published May 2026. (Source for the ~2-fold estimate, NAION incidence range, disc-at-risk and systemic risk factors, the discontinuation position, and the neuroprotection note.) Link
2. European Medicines Agency, Pharmacovigilance Risk Assessment Committee. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy. June 2025. Link
3. Medicines and Healthcare products Regulatory Agency (UK). Drug Safety Update: semaglutide and non-arteritic anterior ischaemic optic neuropathy. February 2026.
4. Hathaway JT, Shah MP, Hathaway DB, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmology. 2024;142:732–739. (The four- to seven-fold figures and the referral-center limitations.)
5. Two cohort studies on GLP-1 receptor agonists and ischemic optic neuropathy. Annals of Internal Medicine. July 2026. (US type 2 diabetes cohort with SGLT-2 inhibitor comparator; Swedish nationwide cohort. Source for 8.5 vs 5.5 per 10,000.)
6. American Optometric Association, Evidence-based Optometry Committee. Glucagon-like Peptide-1 Receptor Agonists and Ocular Health: Guidance for Optometric Practice. June 2025. (Andrew Morgenstern, OD, quoted in AOA coverage of this report.)
7. Novo Nordisk. Wegovy (semaglutide) injection — current FDA prescribing information. Accessed July 2026 via FDA Drugs@FDA. (Source for 4.0% vs 2.7%.) Link
8. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016;375:1834–1844. (Source for 3.0% vs 1.8%.)
9. Vilsbøll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes, Obesity and Metabolism. 2018;20:889–897. (Source for the 8.2% vs 5.2% stratification.)
10. Cohort study of GLP-1 receptor agonists and neovascular age-related macular degeneration in older adults with diabetes. JAMA Ophthalmology. 2024. (Ontario, Canada; source for 93/46,334 vs 88/92,668.)
11. Alkabbani W, Cromer SJ, Patorno E. Neovascular Age-Related Macular Degeneration and GLP-1 RAs. JAMA Ophthalmology. 2025;143:1077. (Non-replication of the wet AMD finding.)
12. Lakhani M, Kwan ATH, Mihalache A, et al. Association of Glucagon-Like Peptide-1 Receptor Agonists with Optic Nerve and Retinal Adverse Events. American Journal of Ophthalmology. 2025;277:148–168. (Contrary evidence — analyses finding no increased NAION risk.)
